Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction.

Cancers (Basel) · 2026 · PMC13162686 · PMID 42122129

Europe PMC DOI

hedged sentence

0.0736

closest p · 1.5× alpha

0.0736

boldest claim

The sentences

did not reach statistical significancep = 0.0736so close (0.05 < p ≤ 0.1)

By contrast, median OS was 44 months in the BEV group and 50 months in the combined OLA group, but the OS difference did not reach statistical significance (HR 0.60, 95% CI 0.34–1.05; p = 0.0736).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.